Relay Therapeutics RLAY
NASDAQ RLAY
$18.05 -0.31 (-1.69%)
At close: Sep 30, 2026 · 4:00 PM EDT

Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Updated

Relay Therapeutics' Current Deferred Revenue was $7.68 million in Q4 2024.

Analysis

Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024) Analysis & Trends

From Q2 2021 onward, Relay Therapeutics has reported Current Deferred Revenue for 8 quarters.

  • Current Deferred Revenue shows a three-year compound annual growth rate of 214.0% (FY2021 to FY2024).
  • In earlier years, Current Deferred Revenue was $248,000 in FY2021.
  • The Q4 2024 figure marks the highest quarterly Current Deferred Revenue in data going back to Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Relay Therapeutics 3.94 Bn 3.94 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 7.68 Mn
Sep 30, 2023 24,000.00
Jun 30, 2023 15,000.00
Jun 30, 2022 83,000.00
Mar 31, 2022 166,000.00
Dec 31, 2021 248,000.00
Sep 30, 2021 331,000.00
Jun 30, 2021 414,000.00
API Access

Relay Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RLAY&period=max&api_key=YOUR_API_KEY